Zurampic
Ironwood returns US Zurampic rights to AstraZeneca, announces operational cuts
August 7, 2018Manufacturing and Production, Sales and Marketing AstraZeneca, Ironwood, Zurampic, gout, pharma
Ironwood Pharmaceuticals has revealed that it has taken the decision to hand the rights for gout therapy Zurampic (lesinurad) back …
AstraZeneca licenses gout drug Zurampic to Grünenthal in Europe and Latin America
June 2, 2016Business Services, Manufacturing and Production, Sales and Marketing AstraZeneca, Grunenthal, Licencing, Zurampic, gout, sales
UK drugmaker AstraZeneca (LSE: AZN) on Thursday said it has entered into a licensing agreement worth up to $230 million …
AstraZeneca sells US rights for gout treatment to Ironwood Pharmaceuticals
April 27, 2016Research and Development, Sales and Marketing AstraZeneca, Ironwood, Licencing, Zurampic, agreement, exclusive, gout, lesinurad, sales
AstraZeneca (LSE: AZN) has entered into a licencing agreement with Ironwood Pharmaceuticals (NASDAQ: IRWD) which will see the latter granted …
AZ warns of patent losses as revenues fall
February 4, 2016Medical Communications, Sales and Marketing AstraZeneca, Crestor, Zurampic
AstraZeneca announced full-year revenues down 7% to $24.7 billion, and Q4 sales down 5% to $6.4 billion, as the London-based …
FDA approves AstraZeneca’s gout drug Zurampic
December 23, 2015Sales and Marketing AstraZeneca, FDA, Zurampic, gout, lensinurad
The US FDA has approved AstraZeneca’s Zurampic to treat high levels of uric acid in the blood. The drug is …
FDA backs AZ gout drug despite safety concerns
October 26, 2015Sales and Marketing AstraZeneca, Zurampic, gout, lesinurad
FDA reviewers have recommended approving AstraZeneca’s new gout therapy Zurampic, which the company purchased in a $1.3 billion buyout, despite …
